Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0ERYUF
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
Felmetatug vedotin
|
|||||
| Synonyms |
felmetatug vedotin; SGN-B7H4V; PF-08046048
Click to Show/Hide
|
|||||
| Organization |
Seagen (Top20 MNC) (Originator)
|
|||||
| Drug Status |
Phase 1 (discontinued)
|
|||||
| Drug-to-Antibody Ratio |
~4
|
|||||
| Structure |
|
|||||
|
|
||||||
| Antibody Name |
Felmetatug
|
Antibody Info | ||||
| Antigen Name |
V-set domain-containing T-cell activation inhibitor 1 (VTCN1)
|
Antigen Info | ||||
| Payload Name |
MMAE
|
Payload Info | ||||
| Therapeutic Target |
Microtubule (MT)
|
Target Info | ||||
| Linker Name |
Mc-Val-Cit-PABC
|
Linker Info | ||||
| Conjugate Type |
Random Cysteines
|
|||||
| Combination Type |
vedotin
|
|||||
| Elimination |
In kinetic analyses of this drug, it was found that over a 1-week span, 17% of the total administered MMAE was retrieved in feces and 6% in urine. This excretion primarily involved the unchanged drug. The mean clearance of enfortumab vedotin and free MMAE was 0.10 L/h and 2.7 L/h, respectively. The clearance of MMAE appears to be limited by its rate of release from enfortumab vedotin.
|
|||||
The indication landscape of This ADC(2027 Update)
The clinical trial pipeline of This ADC(2027 Update)
| Indication | Phase 1 | Phase 1/2 | Phase 2 | Phase 2/3 | Phase 3 | New Drug Application | Approved | ||
|---|---|---|---|---|---|---|---|---|---|
| Biliary tract cancer |
1 Trials
|
||||||||
| Breast cancer |
1 Trials
|
||||||||
| Endometrial cancer |
1 Trials
|
||||||||
| Fallopian tube cancer |
1 Trials
|
||||||||
| Lung cancer |
1 Trials
|
||||||||
| Ovarian cancer |
1 Trials
|
||||||||
| Peritoneal cancer |
1 Trials
|
||||||||
| Unspecific solid tumor |
1 Trials
|
General Information of The Activity Data Related to This ADC
Full List of Activity Data of This Antibody-drug Conjugate
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Patients Enrolled |
Locally advanced unresectable or metastatic solid tumors.
|
||||
| Administration Dosage |
.
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT05194072 | Clinical Status | Phase 1 | ||
| Clinical Description | A phase 1 study of SGN-B7H4V in advanced solid tumors. | ||||
| Experiment 2 Reporting the Activity Date of This ADC | [2] | ||||
| Patients Enrolled |
Eligible participants have locally advanced/metastatic solid tumors (ovarian, breast, lung, etc.), ECOG 0-1, measurable disease (RECIST v1.1), and tumor tissue for analysis. Key exclusions: recent malignancies (≤3 years), active brain metastases (unless stable ≥4 weeks post-treatment), prior MMAE/B7-H4 therapy, Grade ≥2 neuropathy, or active corneal disease.
Click to Show/Hide
|
||||
| Administration Dosage |
.
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT05194072 | Clinical Status | PHASE1 | ||
| Clinical Description | A Phase 1 Study of SGN-B7H4V in Advanced Solid Tumors | ||||
| Primary Endpoint |
Safety will be assessed through AE monitoring up to 5 years post-treatment, including laboratory abnormalities and DLTs (within 28 days of dosing), with overall safety evaluated across dose levels.
|
||||
| Other Endpoint |
Efficacy endpoints include confirmed ORR, CRR, DOR, PFS, and iDFS tracked up to 5 years per RECIST v1.1. PK parameters (AUC, Cmax, Tmax, t1/2, Ctrough) and ADA incidence will be analyzed descriptively over 3 years post-treatment.
|
||||
References